Exenatide: a new promising antidiabetic agent
- PMID: 20582183
- PMCID: PMC2883206
- DOI: 10.4103/0250-474X.62228
Exenatide: a new promising antidiabetic agent
Abstract
Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin.
Keywords: Exenatide; exendin-4; glucagon-like peptide-1; glycosylated hemoglobin; type 2 diabetes mellitus.
Figures
Similar articles
-
Is exenatide a useful addition to diabetes therapy?Endocr Pract. 2006 May-Jun;12(3):307-14. doi: 10.4158/EP.12.3.307. Endocr Pract. 2006. PMID: 16772206 Review.
-
Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568.Drugs R D. 2004;5(1):35-40. doi: 10.2165/00126839-200405010-00007. Drugs R D. 2004. PMID: 14725490 Review.
-
Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.Can J Diabetes. 2014 Aug;38(4):269-72. doi: 10.1016/j.jcjd.2013.10.006. Epub 2014 May 3. Can J Diabetes. 2014. PMID: 24797495
-
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?Diabetes Metab Res Rev. 2019 Jan;35(1):e3070. doi: 10.1002/dmrr.3070. Epub 2018 Oct 4. Diabetes Metab Res Rev. 2019. PMID: 30156747 Review.
-
Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.Rev Recent Clin Trials. 2007 Jan;2(1):77-84. doi: 10.2174/157488707779318053. Rev Recent Clin Trials. 2007. PMID: 18473991
Cited by
-
Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.Diabetes Metab Syndr Obes. 2020 Oct 12;13:3627-3635. doi: 10.2147/DMSO.S265399. eCollection 2020. Diabetes Metab Syndr Obes. 2020. PMID: 33116714 Free PMC article. Review.
-
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications.Ther Adv Endocrinol Metab. 2024 Jan 27;15:20420188231222367. doi: 10.1177/20420188231222367. eCollection 2024. Ther Adv Endocrinol Metab. 2024. PMID: 38288136 Free PMC article. Review.
-
Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review.Pharmaceuticals (Basel). 2022 Jun 19;15(6):764. doi: 10.3390/ph15060764. Pharmaceuticals (Basel). 2022. PMID: 35745683 Free PMC article. Review.
-
Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.Drug Alcohol Depend. 2021 Apr 1;221:108614. doi: 10.1016/j.drugalcdep.2021.108614. Epub 2021 Feb 15. Drug Alcohol Depend. 2021. PMID: 33621809 Free PMC article. Clinical Trial.
References
-
- Patel SK, Goyal RK, Anand IS, Shah JS, Patel HU, Patel CN. Glucagon like peptide-1: A new therapeutic target for diabetes mellitus. Indian J Pharmacol. 2006;38:231–7.
-
- Gagliardi L, Wittert G. Management of obesity in patients with type 2 diabetes mellitus. Curr Diabetes Rev. 2007;3:95–101. - PubMed
-
- Mudaliar S. New frontiers in the management of type 2 diabetes. Indian J Med Res. 2007;125:275–96. - PubMed
-
- Available from: http://www.wikipedia.org/wiki/Exenatide. [accessed on 2007 Jul 2]
-
- Kaushal S, Chopra SC, Arora S. Exenatide: An incretin-mimetic agent. Indian J Pharmacol. 2006;38:76–8.
LinkOut - more resources
Full Text Sources